Home
overview

Building on last year’s conference on Therapeutic Cancer Drugs, SMi have produced a unique conference which deals exclusively with the crucial issues surrounding new developments and strategies in development and marketing of chemotherapeutic agents

The big ‘C’ is the second most common cause of death in the western world, Breakthroughs in understanding of biology have allowed design and development of drugs that strike at the heart of cancers without crippling side effects or damaging the surrounding tissue.

Being able to fire such direct hits, rather than badly aimed broadsides, will allow the industry to provide cures for patients and also secure big profits. Developing the right weaponry to attack the various forms of cancer will allow great gains in the marketplace.

Using a panel of distinguished speakers, this conference will cover the preclinical and clinical development of new therapeutics and the strategies the world leaders from both the pharmaceutical and biotechnology companies are using to secure their lead in the global markets

Conference programme

8:30 Registration and Coffee

9:00 Chairman’s Opening Remarks

Dr Roy Drucker

Dr Roy Drucker, General Manager, Technomark

9:10 THE WAR AGAINST THE COSTS OF CANCER

Dr Lawrence Piro

Dr Lawrence Piro, President and CEO, Salick Health Care

  • The heaviest cost of cancer treatment arises from the need for long term care
  • The cost of drugs is only a small part of the cost of cancer care
  • Providing disease management services for the cancer
  • The "for-profit" disease management arena
  • Disease management is increasingly attractive to governments looking to bring down their healthcare bills
  • Effective analysis of drug treatments and regimens
  • 9:40 BUSINESS STRATEGIES FOR ONCOLOGY

    Jim Bianco

    Jim Bianco, President and CEO, Cell Therapeutics Inc.

  • Targeting major markets of unmet needs
  • Developing products through mid to late stage clinical trials - collaborative strategies
  • Creating drug discovery platforms for new products
  • Oncology focus - Developing drugs that alleviate serious side effects - Combating multi-drug resistance
  • Expanding product portfolios by acquiring new products and technologies
  • 10:20 CLINICAL EVALUATION OF CANCER THERAPY

    Dr Sarah Hatty

    Dr Sarah Hatty, Head of European Oncology, Eli Lilly

  • Assessing efficacy and safety of oncolytic agents in clinical development
  • Toxicity assessment of therapeutics - is it the drug or the disease?
  • The use of quality of life and health economics assessments in trials
  • Developing innovative end-points to clinical trials
  • Giving patients therapeutic options that relieve symptoms and minimise the side effects of treatment
  • What’s innovative: The future of clinical oncology
  • 11:00 Morning Coffee

    11:20 DEVELOPING DRUG CANDIDATES

    Paul Bevan

    Paul Bevan, Research Director, Xenova Therapeutics

  • Developing drug candidates through optimisation and clinical trials
  • P-glycoprotein pump inhibitors - combat multidrug resistance in cancer
  • Initial clinical development - studying safety tolerance and pharmacokinetics
  • Regulatory filings for Phase II trials
  • XR9576 - tackling cancer resistance
  • 12:00 DEVELOPMENT AND MANUFACTURE OF ONCOLOGY PRODUCTS

    Thomas M Speace

    Thomas M Speace, VP Marketing and Business Development, Gensia Sicor

  • Focus on development of quality oncology products
  • Growing a portfolio - developing and manufacturing own injectable products
  • Contract manufacturing agreements with other pharma companies
  • Partnering to drive development of new products
  • Vertical integration - a key to offering unique capabilities in product development
  • 12:40 Lunch

    14:00 VECTORS FOR GENE THERAPY

    Yawen Chiang

    Yawen Chiang, Senior Director, Oncology Gene therapy, RPR Gencell

  • Systemic targeted delivery of gene therapy-based cancer treatments
  • The benefits of direct action by gene therapy in oncological treatment
  • Licensing novel technology for delivery - ‘Trojan Horse’ technology
  • Vitamin receptor technology for targeting anti-cancer treatments
  • Range of genetic regulators for attacking cancerous cells
  • p53, ras
  • 14:40 NEW INDICATIONS

    Dr Iain Sim

    Dr Iain Sim, Global Product Leader for Xeloda, Hoffman-La Roche

  • The need for new and more effective treatments against cancer
  • Xeloda in the treatment of breast cancer
  • New indications and developments - extending the product life cycle
  • The continual development of innovative oncology products
  • 15:20 Afternoon Tea

    15:40 CANCER VACCINES

    Dr Anthony Walker

    Dr Anthony Walker, Chief Executive Officer, Onyvax

  • Tumour vaccines and expected clinical developments
  • Raising the finance to fund research
  • Funding both the research and clinical development of cancer vaccines
  • Competing and collaborations with the larger players
  • Research collaborations
  • The need for a pipeline of cancer products
  • 16:20 ZENECA DIAGNOSTICS

    Steven Little

    Steven Little, R and D Manager, Zeneca Diagnostics

  • Applications and technologies of gene analysis
  • Mutation analysis and detection of LOH
  • Gene expression analysis
  • Colorectal cancer staging
  • Chemotherapy selection
  • Bladder selection monitoring
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration and Coffee

    9:00 Chairman’s Opening Remarks

    Dr Roy Drucker

    Dr Roy Drucker, General Manager, Technomark

    9:10 THE PATIENTS AND CANCER

    Dr Elaine Farmery

    Dr Elaine Farmery, Medical Director, Marie Curie Cancer Care

  • What is the role of Marie Curie Cancer Care?
  • Research into areas of unmet need
  • Working with the patients and the pharmaceutical industry to address needs
  • New therapies and new policies - fitting the drugs to the patients
  • Healthcare and cancer - long term needs and objec
  • What does the future hold for cancer patients?
  • 9:40 APPLIED DEVELOPMENT IN ONCOLOGY

    David Snary

    David Snary, Manager, Imperial Cancer Research Technology

  • The link between basic research and its application to clinical development
  • The commercialisation of research opportunities
  • Identifying and developing opportunities
  • Current applications and programmes
  • Transitional research and the input from commercial sources
  • 10:20 DEVELOPMENT AND COMMERCIALISATION OF CANCER DRUGS

    Rifat Pamukcu

    Rifat Pamukcu, Chief Scientific Officer and SVP R and D, Cell Pathways

  • Orally active drug with novel mechanism
  • Inducing apoptosis in precancerous and cancerous cells with no effect on normal cells
  • Potential treatment across a range of indications
  • Clinical trials for PREVATAC‘ : filing applications for new drugs
  • Future plans and development of pipeline products
  • 11:00 Morning Coffee

    11:20 NOVEL CHEMOTHERAPEUTIC AGENTS

    Julian Adams

    Julian Adams, EVP Research and Development, ProScript

  • Small molecule inhibitors in cancer indications
  • The UPP pathway and general cell regulation - targets for therapeutic intervention
  • Exploring novel therapeutic approaches for the treatment of cancer -PS-341
  • Anticancer activity and improving treatment outcomes in combination therapies
  • Overcoming drug resistance - restoring sensitivity
  • Collaborations to advance clinical development
  • 12:00 ANGIOGENESIS INHIBITORS

    Björn Nordenvall

    Björn Nordenvall, President and CEO, OXiGENE

  • Departing from the conventional approaches to cancer therapy
  • Tumour vascular targeting and angiogenesis
  • Different mode of action for Combretastatin - destroying tumour blood vessels
  • Determining the safety and efficacy of Combretastatin and evaluation in combination therapy with other cancer treatments
  • Creating a solid pipeline of anticancer therapies and progress through clinical development
  • 14:00 DEVELOPMENT OF ANTISENSE DRUGS FOR CANCER

    Dr R Russell Martin

    Dr R Russell Martin, SVP Drug Development, Hybridon

  • Antisense uses rational drug design against specific genetic targets
  • Many compounds are effective in cell culture and tumor xenografts
  • Initial compounds hit signalling pathways and growth factors
  • Encouraging early results are reported from systemic use in cancer
  • Future will emphasize combinations with cytotoxics and other agents.
  • Improved second-generation compounds are in early clinical trials, e.g., Hybridon’s GEM‚231 against Protein Kinase A RIa.
  • 14:40 CREATING NEW CANCER THERAPEUTICS

    Mitchel Sayare

    Mitchel Sayare, Chairman and CEO, Immunogen

  • Antibody-based approach to cancer therapies
  • Tumour activated prodrugs - monoclonal identification of cancer cells
  • Effective targeting and delivery of cancer drugs - elevated concentration with limited side effects
  • Fast-track development issues - getting innovative products through regulatory bodies into the market
  • Collaborations to accelerate clinical development
  • Cost of and return from developing therapies for cancer
  • 15:20 Afternoon Tea

    15:40 ANTIBODY THERAPIES IN CANCER

    Donald L Drakeman

    Donald L Drakeman, President and CEO, Medarex

  • Developing antibody-based technologies
  • Bispecific antibodies: enhancing and directing the body’s own immune system to fight disease
  • MDX-220: Bispecific antibody targeting TAG-72 positive cancers
  • Ability to detect and to bind to tumours
  • Adding new weapons to the pipeline of anticancer therapeutics
  • Initiating and continuing trials with Bispecific antibody technology
  • 16:20 THALOMID AND CANCER

    Jerome B. Zeldis

    Jerome B. Zeldis, Vice President, Medical Affairs, Celgene Corporation

  • Disease Overview including current therapeutic options
  • Mechanism of thalidomide's action: Angiogenesis?, Cytokine Modulation?
  • Current Status of THALOMID Multiple Myeloma Program
  • The S.T.E.P.S.* Program for the commercial distribution and use of thalidomide
  • Potential efficacy of THALOMID in the treatment of other oncological conditions including glioblastoma multiforme
  • Possible successors to THALOMID
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.